Polatuzumab vedotin Chemische Eigenschaften,Einsatz,Produktion Methoden
Synthese
The drug was developed by Genentech (a division of Roche) using ADC linker-payload technology licensed and developed by Senter and colleagues at Seagen (formerly Seattle Genetics). This same linker-payload and conjugation strategy was also incorporated into the preparation of Brentuximab Vedotin (approved in 2011) and Enfortumab Vedotin (approved in 2019). Although no clear preparation method for Pelotonuzumab is found in the patent literature, the drug was developed using Seagen technology, and its synthesis process is generally described in the scheme and is very similar to that described for Brentuximab Vedotin, except that slightly different reagents are used.
Polatuzumab vedotin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
